Balicatib

Balicatib (AAE581) is a potent, orally active and selective cathepsin K inhibitor with IC50 values of 22, 61, 48, 2900 nM for cathepsin K, cathepsin B, cathepsin L, cathepsin S, respectively. Balicatib inhibits bone turnover, decreases bone formation rates. Balicatib has the potential for the research of osteoporosis[1][2].

Product Specifications

CAS Number

[354813-19-7]

Product Name Alternative

AAE581

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Cathepsin

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Balicatib.html

Purity

98.25

Solubility

DMSO : 75 mg/mL (ultrasonic)

Smiles

CCCN1CCN(C2=CC=C(C(NC3(C(NCC#N)=O)CCCCC3)=O)C=C2)CC1

Molecular Formula

C23H33N5O2

Molecular Weight

411.54

Precautions

H315, H319, H335

References & Citations

[1]Jerome C, et al. Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. Osteoporos Int. 2012 Jan;23 (1) :339-49.|[2]Gauthier JY, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008 Feb 1;18 (3) :923-8.